Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$16,043,610
in 4 filings, $16.0M under 10b5-1 plans

Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Savitz Ryan −$11.2M EVP, CFO & CBO sold 100% of stake
  2. Randhawa Simrat −$2.5M EVP, Head of R&D sold 85% of stake
  3. CARR EDWARD −$2.0M CHIEF ACCOUNTING OFFICER sold 100% of stake
  4. Read Simon −$327K Director sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2022-05-17 Deardorf Caren Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +50,000 50,000
2022-02-15 GARDNER JASON See Remarks Grant or award · Stock Option (Right to Buy) +187,500 187,500
2022-02-15 Humphrey Jeffrey Chief Medical Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2022-02-15 Deardorf Caren Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2022-02-15 Stants Kristen Chief People Officer Grant or award · Stock Option (Right to Buy) +85,000 85,000
2022-02-15 Nichols David Wayne Chief Technical Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2022-02-15 Olson Lisa See Remarks Grant or award · Stock Option (Right to Buy) +100,000 100,000
2022-02-15 Mahoney Stephen F. See Remarks Grant or award · Stock Option (Right to Buy) +130,000 130,000
2022-02-15 Beetham Thomas W. See Remarks Grant or award · Stock Option (Right to Buy) +75,000 75,000
2021-10-01 Humphrey Jeffrey Chief Medical Officer Grant or award · Stock Option (Right to Buy) +275,000 275,000
2021-09-16 Stants Kristen Chief People Officer Sale −5,736 $6.73 $39K 14,264
2021-09-16 Mahoney Stephen F. See Remarks Sale −5,736 $6.73 $39K 14,264
2021-09-16 Deardorf Caren Chief Commercial Officer Sale −6,238 $6.73 $42K 13,762
2021-09-16 GARDNER JASON See Remarks Sale −14,340 $6.73 $97K 286,872
2021-09-16 Beetham Thomas W. See Remarks Sale −6,103 $6.73 $41K 13,897
2021-09-16 Olson Lisa See Remarks Sale −5,736 $6.73 $39K 14,264
2021-09-16 Nichols David Wayne Chief Technical Officer Sale −5,694 $6.73 $38K 14,306
2021-09-14 Olson Lisa See Remarks Grant or award +20,000 20,000
2021-09-14 Stants Kristen Chief People Officer Grant or award +20,000 20,000
2021-09-14 Deardorf Caren Chief Commercial Officer Grant or award +20,000 20,000

Page 15 of 24 · 470 trades